• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Zomedica And 3 Other Stocks Under $3 Insiders Are Buying

    5/14/24 9:01:46 AM ET
    $CERS
    $ZOM
    EDP Services
    Technology
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $CERS alert in real time by email

    The Dow Jones index closed lower by over 80 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

    Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform.

    Earth Science Tech

    • The Trade: Earth Science Tech, Inc. (OTC:ETST) Director Yovan Arturo Sanchez bought a total of 10,500 shares at an average price of $0.10. To acquire these shares, it cost around $1,050.
    • What's Happening: On Jan. 29, Earth Science Tech announced a $5 million common stock repurchase program.
    • What Earth Science Tech Does: Earth Science Tech Inc is a diversified holding company. Currently, the company is focused on emerging prospects in the health and wellness industry.

    Nanophase Technologies

    • The Trade: Nanophase Technologies Corporation (OTC:NANX) Director R Janet Whitmore acquired a total of 5,300 shares at an average price of $1.40. To acquire these shares, it cost around $7,420.
    • What's Happening: On April 23, Nanophase Technologies announced financial results for the first quarter ended March 31, 2024.
    • What Nanophase Technologies Does: Nanophase Technologies Corp is engaged in the production of engineered nanomaterial solutions and larger, sub-micron, materials such as personal care sunscreens, architectural coatings, industrial coating applications, and abrasion-resistant additives, plastics additives, medical diagnostics, energy.

    Cerus

    • The Trade: Cerus Corporation (NASDAQ:CERS) Director Jami K Nachtsheim acquired a total of 2,000 shares at an average price of $1.79. The insider spent around $3,578 to buy those shares.
    • What's Happening: On May 2, Cerus said product revenue during the first quarter of 2024 was $38.4 million, up from $31.0 million in the year-ago period.
    • What Cerus Does: Cerus Corp is a biomedical products company focused on the field of blood transfusion safety.

    Zomedica

    • The Trade: Zomedica Corp. (NYSE:ZOM) CEO Larry C Heaton II acquired a total of 100,000 shares at an average price of $0.14. The insider spent around $14,200 to buy those shares.
    • What's Happening: On May 9, Zomedica reported a year-over-year decease in first-quarter GAAP EPS results and issued worse-than-expected quarterly sales results.
    • What Zomedica Does: Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians.

    Read This: Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday

    Get the next $CERS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CERS
    $ZOM

    CompanyDatePrice TargetRatingAnalyst
    Cerus Corporation
    $CERS
    4/12/2024$5.00Buy
    Craig Hallum
    Cerus Corporation
    $CERS
    1/20/2023Buy → Neutral
    BTIG Research
    Cerus Corporation
    $CERS
    1/17/2023$3.75Overweight → Equal-Weight
    Stephens
    Zomedica Corp.
    $ZOM
    1/6/2023$6.00Buy
    Dawson James
    More analyst ratings

    $CERS
    $ZOM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Green Kevin Dennis

    4 - CERUS CORP (0001020214) (Issuer)

    4/3/26 5:51:28 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form 4 filed by Jensen Chrystal

    4 - CERUS CORP (0001020214) (Issuer)

    4/3/26 5:43:10 PM ET
    $CERS
    EDP Services
    Technology

    Chief Legal Officer Jensen Chrystal sold $187,277 worth of shares (113,008 units at $1.66), decreasing direct ownership by 11% to 946,131 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    3/16/26 7:45:06 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    $ZOM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig Hallum initiated coverage on Cerus with a new price target

    Craig Hallum initiated coverage of Cerus with a rating of Buy and set a new price target of $5.00

    4/12/24 8:00:30 AM ET
    $CERS
    EDP Services
    Technology

    Cerus downgraded by BTIG Research

    BTIG Research downgraded Cerus from Buy to Neutral

    1/20/23 10:02:56 AM ET
    $CERS
    EDP Services
    Technology

    Cerus downgraded by Stephens with a new price target

    Stephens downgraded Cerus from Overweight to Equal-Weight and set a new price target of $3.75

    1/17/23 7:57:35 AM ET
    $CERS
    EDP Services
    Technology

    $CERS
    $ZOM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Cerus Corporation

    SCHEDULE 13G/A - CERUS CORP (0001020214) (Subject)

    3/26/26 5:16:35 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - CERUS CORP (0001020214) (Filer)

    3/16/26 5:18:37 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form 144 filed by Cerus Corporation

    144 - CERUS CORP (0001020214) (Subject)

    3/5/26 5:03:03 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    $ZOM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

    William "Obi" Greenman to become Executive Chairman Leadership changes to take effect July 1, 2026 Cerus Corporation (NASDAQ:CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William "Obi" Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. "Following a thorough succession planning process, this transition represents a natural step as we prepare for the next phase of growth at Cerus," said Frank Witney, lead independent director on the Cerus Board of Directors. "The Board and I are de

    3/16/26 4:05:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

    2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management Cerus Corporation (NASDAQ:CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' pres

    3/2/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    $CERS
    $ZOM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gregory Dean A. bought $31,250 worth of shares (25,000 units at $1.25), increasing direct ownership by 41% to 86,725 units (SEC Form 4)

    4 - CERUS CORP (0001020214) (Issuer)

    8/25/25 3:25:00 PM ET
    $CERS
    EDP Services
    Technology

    Amendment: Director Rowe Jeffrey M bought $96,098 worth of shares (1,439,005 units at $0.07) (SEC Form 4)

    4/A - Zomedica Corp. (0001684144) (Issuer)

    3/27/25 9:56:49 AM ET
    $ZOM
    Pharmaceuticals and Biotechnology
    Health Care

    Director Williams Rodney James bought $6,900 worth of shares (100,000 units at $0.07), increasing direct ownership by 62% to 261,900 units (SEC Form 4)

    4 - Zomedica Corp. (0001684144) (Issuer)

    3/20/25 9:52:31 AM ET
    $ZOM
    Pharmaceuticals and Biotechnology
    Health Care

    $CERS
    $ZOM
    Leadership Updates

    Live Leadership Updates

    View All

    Cerus Appoints Vivek Jayaraman as President and Chief Executive Officer

    William "Obi" Greenman to become Executive Chairman Leadership changes to take effect July 1, 2026 Cerus Corporation (NASDAQ:CERS) today announced that Vivek Jayaraman, Cerus' chief operating officer, will be promoted to president and chief executive officer, effective July 1, 2026. William "Obi" Greenman will become executive chairman of the board of directors. At the time of his appointment, Mr. Jayaraman will join the Board of Directors. "Following a thorough succession planning process, this transition represents a natural step as we prepare for the next phase of growth at Cerus," said Frank Witney, lead independent director on the Cerus Board of Directors. "The Board and I are de

    3/16/26 4:05:00 PM ET
    $CERS
    EDP Services
    Technology

    Diality Appoints Peter Donato as Chief Financial Officer

    Life sciences veteran brings private and public sector expertise to company in midst of growth trajectory Diality Inc., a medical device company that has developed the Moda-flx™ Hemodialysis System, today announced it has named Peter Donato as its chief financial officer. Donato joins the company as it continues to enroll patients in the PRESCRIBE Diality Home Hemodialysis Clinical Trial of its Moda-flx Hemodialysis System while preparing for a limited market release in 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224064413/en/Diality CFO Peter Donato. Donato joins Diality with nearly 35 years of financial leadershi

    2/24/26 7:05:00 AM ET
    $MYGN
    $STIM
    $TFX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Medical/Dental Instruments
    Pharmaceuticals and Biotechnology

    Zomedica Appoints Scott A. Jordan Executive Vice President, Finance & Chief Financial Officer

    Seasoned executive brings a broad skill set to Zomedica's leadership team ANN ARBOR, MI / ACCESSWIRE / December 19, 2024 / Zomedica Corp. (NYSE:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostics and therapeutic products for companion animals, announced that it has appointed Scott A. Jordan as its Executive Vice President, Finance and Chief Financial Officer, effective January 1, 2025."Scott brings a broad range of skills and experience that will be increasingly important to us as we move forward," said Larry Heaton, Zomedica's Chief Executive Officer. We are excited to welcome him to the Zomedica team and look forward to leveraging his expertis

    12/19/24 6:30:00 AM ET
    $ZOM
    Pharmaceuticals and Biotechnology
    Health Care

    $CERS
    $ZOM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cerus Corporation

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    11/12/24 9:53:11 AM ET
    $CERS
    EDP Services
    Technology

    SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    2/14/24 4:21:51 PM ET
    $CERS
    EDP Services
    Technology

    SEC Form SC 13G/A filed by Cerus Corporation (Amendment)

    SC 13G/A - CERUS CORP (0001020214) (Subject)

    2/13/24 5:01:03 PM ET
    $CERS
    EDP Services
    Technology

    $CERS
    $ZOM
    Financials

    Live finance-specific insights

    View All

    Cerus Corporation Announces Full-Year and Fourth Quarter 2025 Financial Results

    2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management Cerus Corporation (NASDAQ:CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' pres

    3/2/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation to Release Fourth Quarter and Full-Year 2025 Financial Results on March 2, 2026

    Cerus Corporation (NASDAQ:CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will

    2/17/26 4:01:00 PM ET
    $CERS
    EDP Services
    Technology

    Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance

    Third Quarter Total Revenue up 19% to $60.2 Million; Record Product Revenue of $52.7 Million, Up 15% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $202 Million - $204 Million Cerus Corporation (NASDAQ:CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update. "We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System. Fu

    11/6/25 4:01:00 PM ET
    $CERS
    EDP Services
    Technology